Cargando…
Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
Autores principales: | Thariat, Juliette, Launay-Vacher, Vincent, Italiano, Antoine, Santini, José, Peyrade, Frederic |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421162/ https://www.ncbi.nlm.nih.gov/pubmed/25983881 http://dx.doi.org/10.1093/ndtplus/sfn039 |
Ejemplares similares
-
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020) -
Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020) -
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021) -
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020) -
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)